CEO Q&A with Marc Loomes at ECO Animal Health Group Plc (LON:EAH)

ECO Animal Health Group Plc (LON:EAH) Chief Executive Officer Marc Loomes caught up with DirectorsTalk for an exclusive interview to discuss the what the company does, Aivlosin regulatory approvals, new developments in upcoming vaccinations and their plans for the near future.

 

Q1: So, I believe this is your first appearance on DirectorsTalk Mark, so welcome. Could you please give a brief background on the company?

A1: ECO Animal Health Group was established in 1993 and was amongst the very first companies to join AIM 2 years later. Today, the company sells its products which are for the treatment of economically important diseases of livestock, principally pigs and poultry, in over 70 countries and employs more 200 staff in 14 regional offices.

We develop new products making extensive use of universities and contract research organisations, obtain marketing authorisations or licenses enabling these products to be sold through the most appropriate channels to market and we utilise third party contract manufacturers to produce our portfolio of products.

 

Q2: You recently announced the receipt of a marketing authorisation in India for the use of Aivlosin in chicken laying eggs for human consumption, could you provide an update on this?

A2: Aivlosin is ECO’s flagship patented product and is used to treat economically important gastrointestinal/gut and respiratory disease in both pigs and poultry.

This new marketing authorisation for chickens producing eggs for human consumption has a 0-day drug withdrawal period for eggs, the only drug in the Indian market with this claim. This allows egg producers to treat mycoplasma infections in laying birds, reducing mortality and egg loss in the laying period without having to discard any eggs.

The first batch of Aivlosin with this new claim on the label are currently en-route to our newly-formed subsidiary, ECO India. We expect to start selling it into the laying market very soon and with 300 million laying birds, India is the third largest market globally.

 

Q3: As well at that Mark, you also recently received European marketing authorisation for Aivlosin in the breeding of chickens, what is the significance of this?

A3: The European Medicines Agency is one of the most stringent regulatory authorities in the world, they have licenses Aivlosin for the use in high value breeding birds which produce eggs for hatching replacement stock. This approval goes straight to both the efficacy and safety of Aivlosin in the most valuable of birds.

We will now rollout this approval beyond the EU into the multi-million dollar large international poultry markets enabling us to capitalise on the considerable global potential of Aivlosin.

 

Q4: Could you explain a bit more about any new developments in upcoming vaccinations and what are ECO’s plans for the near future?

A4: Our vaccine development portfolio is also focussed on swine and poultry and we are targeting both viral and bacterial diseases of economic importance in both species. Amongst our vaccine target, mycoplasma pathogens are a key focus as they will compliment our excellence therapeutic offering against mycoplasma with our Aivlosin range.

Our current priorities are to add to our existing development portfolio by working closely with universities, public research institutions such as The Pirbright Institute, and start-ups where we have a number of exciting potential opportunities undergoing due diligence and contract review at this time. An important aspect of our due diligence is to ensure we have freedom to operate and we’re confident that we can secure exclusivity in key markets.

As a way of de-risking our investment, we plan to take these opportunities through a rigorous proof of concept evaluation in well-designed studies before committing to further development funding. Our pipeline has a mix of well-established concepts as well as novel, potential disruptive technologies and approaches.

 

Q5: So, looking at your chosen sectors, there appears to be a lot of opportunity, could you describe the key drivers behind this and the potential for ECO Animal Health Group?

A5: Food production and animal health are growth markets, the Food and Agriculture Organisation of the United Nations predicts that world meat consumption will double by 2050 with pigs and poultry amongst the fastest growing sectors.

ECO has a global presence with well-established routes to market, we have a strong and developing R&D pipeline which will enable us to expand both geographically and across indications. We are profitable, we are cash generative and I believe that the company has enormous potential.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
ECO Animal Health Group plc

More articles like this

ECO Animal Health Group plc

Eco Animal Health delivering on earnings and R&D progress (VIDEO)

Eco Animal Health Group plc (LON:EAH) CEO David Hallas joins DirectorsTalk Interviews to discuss interim results for the six months ended 20th September. David talks us through the highlights, improved Chinese pork prices, excitement over new product developments, what

ECO Animal Health Group plc

ECO Animal Health Group appoint Haysmacintyre LLP as auditor

Following a competitive tender process overseen by the Group’s Audit & Risk Committee, ECO Animal Health Group (LON:EAH) has announced the resignation of BDO LLP as auditor and the appointment, with immediate effect, of Haysmacintyre LLP as auditor for the

ECO Animal Health Group plc

ECO Animal Health AGM to be held on 26 September 2022

ECO Animal Health Group plc (LON:EAH) has announced the publication of the following documents on the Company’s website: www.ecoanimalhealthgroupplc.com/investor-relations.aspx. ·     Annual Report and Accounts for the year ended 31 March 2022 ·    Notice of Annual General Meeting to be held

ECO Animal Health Group plc

ECO Animal Health delivers record China revenue in Q1

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has provided an update to its expected results for the year ended 31 March 2022.  The audit

ECO Animal Health Group plc

ECO Animal Health signs new bank facility agreement with NatWest

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has announced that it has signed a new bank facility agreement with its bank, National Westminster Bank

ECO Animal Health Group plc

ECO Animal Health partners with Moredun Research Institute

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has announced that its wholly owned subsidiary, ECO Animal Health Ltd, has entered into a research partnership

ECO Animal Health Group plc

ECO Animal Health Group pleased with recent trading

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets has provided an unaudited trading update for the financial year ending 31st March 2022. ECO commented in

ECO Animal Health Group plc

ECO Animal Health live investor presentation

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has announced that Marc Loomes, CEO, Christopher Wilks, CFO, and Hafid Benchaoui, Global Head of R&D, will be

ECO Animal Health Group plc

ECO Animal Health appoint Tracey James as a Non-Executive Director

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health market, is pleased to announce the appointment of Tracey James as a Non-Executive Director with immediate effect. Tracey

No more posts to show